Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NP1867
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : NeoPhore
Deal Size : $39.5 million
Deal Type : Series B Financing
NeoPhore Raises £9.6M in Series B Extension to Advance Drug Discovery Pipeline
Details : The net proceeds will be used to progress NeoPhore's lead canditate, NP1867, an oral, small molecule, first-in-class MMR inhibitor, through early pre-clinical development in solid tumours.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 02, 2024
Lead Product(s) : NP1867
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : NeoPhore
Deal Size : $39.5 million
Deal Type : Series B Financing
Lead Product(s) : NXP800
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Nuvectis Pharma
Deal Size : $15.0 million
Deal Type : Licensing Agreement
Details : Nuvectis also announced that it has licensed exclusive worldwide rights to develop and commercialize the drug candidate NXP800, a novel, oral small molecule inhibitor of the heat shock factor 1 (HSF1) pathway from the CRT Pioneer Fund LP .
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 26, 2021
Lead Product(s) : NXP800
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Nuvectis Pharma
Deal Size : $15.0 million
Deal Type : Licensing Agreement
Reset All
